Literature DB >> 30582713

Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology.

Matteo Bassetti1, Alessandro Russo1, Elda Righi1, Elisabetta Dolso1, Maria Merelli1, Federica D'Aurizio1, Assunta Sartor1, Francesco Curcio1.   

Abstract

INTRODUCTION: Bloodstream infections (BSI) and their evolution to sepsis or septic shock are one of the most important causes of morbidity and mortality; for this reason, arapid recognition and diagnosis of these infections are crucial to improve patients' outcome. Area covered: Procalcitonin (PCT) is considered an important biomarker for diagnosis of infection, routinely used to identify patients developing severe bacterial infections. In this scenario, management of BSI is complicated by the increasing rate of multidrug-resistantstrains, and an early recognition of severe infections is mandatory. Moreover, an appropriate use and prescription of antibiotics is important to reduce the risk of development of further antibiotic resistances. Expert opinion: we reviewed recent literature about the use of PCT in bacteremic patients to determine its role to predict infections, severity of clinical condition and antibiotic therapy duration; its role was defined in many studies to reduce duration of antibiotic treatment, especially in critically ill patients and for lower respiratory tract infections. Moreover, we reported recent studies in which PCT showed ahigh performance to detect precociously infections due to Gram-negativestrains. Data from the literature confirm that PCT should not be used as astand-alonetest in the absence of clinical judgment.

Entities:  

Keywords:  C-reactive protein; Enterobacteriaceae; Gram-negative; Procalcitonin; bacteremia

Mesh:

Substances:

Year:  2018        PMID: 30582713     DOI: 10.1080/14787210.2019.1562335

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

1.  Diagnostic Accuracy of Procalcitonin Compared to C-Reactive Protein and Interleukin 6 in Recognizing Gram-Negative Bloodstream Infection: A Meta-Analytic Study.

Authors:  Liying Lai; Yijie Lai; Hao Wang; Liang Peng; Ning Zhou; Yi Tian; Yongfang Jiang; Guozhong Gong
Journal:  Dis Markers       Date:  2020-01-23       Impact factor: 3.434

Review 2.  Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic.

Authors:  Alessandro Russo; Vincenzo Olivadese; Enrico Maria Trecarichi; Carlo Torti
Journal:  J Clin Med       Date:  2022-04-19       Impact factor: 4.964

3.  Performance verification of a new domestic chemiluminescence detection system.

Authors:  Lihua Yang; Lin Wang; Yuji Gong; Wenpu Shi; Xiaohu An; Huifei Zheng
Journal:  Ann Transl Med       Date:  2020-11

4.  Diagnostic Value and Prognostic Significance of Procalcitonin Combined with C-Reactive Protein in Patients with Bacterial Bloodstream Infection.

Authors:  Yan Zhang; Mei La; Jihong Sun; Mimi Chen; Dandan Liu; Xiaolin Liu; Yating Kang
Journal:  Comput Math Methods Med       Date:  2022-08-11       Impact factor: 2.809

5.  Clinical characteristics, drug resistance and death risk factors of Burkholderia cepacia infection in hematopoietic stem cell transplant patients.

Authors:  Yan Jia; Ya Liu; Yi Liu; Kaitai Yang; Yanfeng Liu
Journal:  BMC Infect Dis       Date:  2022-10-06       Impact factor: 3.667

Review 6.  The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review.

Authors:  Alessandro Lazzaro; Gabriella De Girolamo; Valeria Filippi; Giuseppe Pietro Innocenti; Letizia Santinelli; Giancarlo Ceccarelli; Enrico Maria Trecarichi; Carlo Torti; Claudio Maria Mastroianni; Gabriella d'Ettorre; Alessandro Russo
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

7.  Diagnostic Value of Procalcitonin and C reactive Protein for Infection and Sepsis in Elderly Patients.

Authors:  Çiler Zincircioğlu; Kazim Rollas; Işil Güldoğan; Aykut Saritaş; Hüseyin Özkarakaş; Gürsel Ersan; Nimet Şenoğlu
Journal:  Turk J Med Sci       Date:  2021-08-04       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.